Why the study?
Does intravenous epoprostenol improve maternal and fetal outcomes in pregnant women with severe primary pulmonary hypertension?
Does intravenous epoprostenol improve maternal and fetal outcomes in pregnant women with severe primary pulmonary hypertension?
Intravenous epoprostenol can be used to successfully manage severe pulmonary arterial hypertension during pregnancy, though fetal and neonatal risks remain uncertain.
May support epoprostenol for maternal stabilization in severe PAH pregnancy; leaves neonatal safety uncertain and hypothesis-generating.
Background Pulmonary arterial hypertension carries a high risk of mortality in pregnancy. Recent advances in treatment may improve disease course and allow for successful management of the pregnancy. Case Report We present the case of a 20-year-old gravida 1, para 0 with diagnosis of severe primary pulmonary hypertension. The patient was managed with epoprostenol (prostacyclin) infusion via an indwelling catheter, which was initiated at 23 weeks' gestation. The dose was adjusted to the patient's symptoms and a successful vaginal delivery was achieved at 36 weeks' gestation. Although maternal postpartum course was uncomplicated, unexplained neonatal demise occurred at 11 days of life. Conclusion Successful management of pulmonary hypertension in pregnancy can be accomplished with a multidisciplinary approach and intensive therapy. Long-term effects of epoprostenol on fetal or neonatal well-being are unknown.
No takes yet. Share an insight, caveat, or question.
Ruiz et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: